Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3535-3542

  Kao, L Mark ^a   Bush, Karen ^a   Barnewall, Roy ^b   Estep, James ^b   Thalacker, Frederic W ^c   Olson, Pamela H ^b   Drusano, George L ^d   Minton, Neil ^a   Chien, Shuchean ^a   Hemeryck, Alex ^e   Kelley, Michael F ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c 206 Carnegie Center   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DRUG VEHICLE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BACTERIUM CULTURE; COMPUTER SIMULATION; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FATALITY; FEMALE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SPORE GERMINATION; TREATMENT DURATION;

AEROSOLS; ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACILLUS ANTHRACIS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; FEMALE; HUMANS; INHALATION EXPOSURE; MACACA MULATTA; MALE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; SPORES, BACTERIAL;

EID: 33750603831     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00090-06     Document Type: Article

References (19)

1. Aminimanizani, A., P. Beringer, and R. Jellife. 2001. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. 40(3):169-187.
2. Cavallo, J. D., F. Ramisse, M. Giradet, J. Vaissaire, M. Mock, and E. Hernandez. 2002. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob. Agents Chemother. 46:2307-2309.
3. Center for Drug Evaluation and Research. 2002. Draft guidance for industry, inhalational anthrax (post-exposure)-developing antimicrobial drugs. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, D.C.
4. Chien, S., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Nataranjan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
5. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial testing. Ninth M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
6. Deziel, M., R. H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
7. Fish, D. N., and A. T. Chow. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32(2):101-119.
8. Fish, D. N. 2003. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones.' Exp. Rev. Antiinfect. Ther. 1:371-387.
9. Friedlander, A. M., W. L. Welkos, M. L. M. Pitt, J. W. Ezzell, P. L. Worsham, K. J. Rose, B. E. Ivins, J. R. Lowe, G. B. Howe, P. Mikesell, and W. B. Lawrence. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1239-1242.
10. Gerberding, J. 2002. Inhalation anthrax revisited: a view from the Centers for Disease Control. Am. J. Med. 112:2.
11. Gleiser, C. A., C. C. Berdjis, H. Hartman, and W. S. Gochenour. 1963. Pathology of experimental respiratory anthrax in Macaca mulatto. Br. J. Exp. Pathol. 3:416-426.
12. 14C-levofloxacin after single oral administration in the rhesus monkey. Xenobiotica 36:597-613.
13. Henderson, D. W., S. Peacock, and F. C. Belton. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. 54:28-36.
14. Ivins, B. E., M. L. Pitts, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
15. Kelly, D. J., J. D. Chulay, P. Mikesell, and A. M. Friedlander. 1992. Serum concentrations of penicillin, doxycycline and ciprofloxacin during prolonged therapy in rhesus monkeys. J. Infect. Dis. 166:1184-1187.
16. Mohammed, M. J., C. K. Marston, T. Popovic, R. S. Weyantand, and F. C. Tenover. 2002. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J. Clin. Microbiol. 40:1902-1907.
17. Siefert, H. M., D. Maruhn, W. Maul, D. Forster, and W. Ritter. 1986. Pharmacokinetics of ciprofloxacin. Arzneimittel-Forschung 36:1496-1502.
18. Wong, F. A., S. J. Juzwin, and S. C. Flor. 1997. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.
19. Zlotos, G., A. Bucker, M. Konzig-Schippers, F. Sorgel, and D. U. Holzgrabe. 1998. Plasma protein binding of gyrase inhibitors. J. Pharm. Sci. 87:215-220.